Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 634

1.

Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.

Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H.

Ann Surg Oncol. 2008 Oct;15(10):2887-93. doi: 10.1245/s10434-008-0048-2. Epub 2008 Jul 18.

PMID:
18636295
2.

Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.

Westphal M, Ram Z, Riddle V, Hilt D, Bortey E; Executive Committee of the Gliadel Study Group.

Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275. Epub 2006 Feb 17.

PMID:
16482400
4.

Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla.

Dyke JP, Sanelli PC, Voss HU, Serventi JV, Stieg PE, Schwartz TH, Ballon D, Shungu DC, Pannullo SC.

J Neurooncol. 2007 Mar;82(1):103-10. Epub 2006 Sep 22.

PMID:
17031552
5.

Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.

Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA, Li K, Olivi A, Wharam MD, Brem H.

Cancer Invest. 2004;22(1):1-9.

PMID:
15069758
6.

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.

Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z.

Neuro Oncol. 2003 Apr;5(2):79-88.

7.

Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.

McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H, Quiñones-Hinojosa A.

J Neurosurg. 2009 Mar;110(3):583-8. doi: 10.3171/2008.5.17557.

8.

Association of preoperative depression and survival after resection of malignant brain astrocytoma.

Gathinji M, McGirt MJ, Attenello FJ, Chaichana KL, Than K, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa A.

Surg Neurol. 2009 Mar;71(3):299-303, discussion 303. doi: 10.1016/j.surneu.2008.07.016. Epub 2008 Sep 11.

PMID:
18786716
9.

The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.

Nagpal S.

Neurosurg Clin N Am. 2012 Apr;23(2):289-95, ix. doi: 10.1016/j.nec.2012.01.004. Epub 2012 Feb 18. Review.

PMID:
22440872
10.

The role of Gliadel wafers in the treatment of high-grade gliomas.

Bregy A, Shah AH, Diaz MV, Pierce HE, Ames PL, Diaz D, Komotar RJ.

Expert Rev Anticancer Ther. 2013 Dec;13(12):1453-61. doi: 10.1586/14737140.2013.840090. Review.

PMID:
24236823
11.

Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD, Brem H, Quiñones-Hinojosa AR.

J Neurosurg. 2009 Jan;110(1):156-62. doi: 10.3171/2008.4.17536.

PMID:
18847342
12.

First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.

Bock HC, Puchner MJ, Lohmann F, Schütze M, Koll S, Ketter R, Buchalla R, Rainov N, Kantelhardt SR, Rohde V, Giese A.

Neurosurg Rev. 2010 Oct;33(4):441-9. doi: 10.1007/s10143-010-0280-7. Epub 2010 Aug 13.

13.
14.

Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel® implantation--incidence, therapeutic strategies, and outcome.

Dörner L, Ulmer S, Rohr A, Mehdorn HM, Nabavi A.

J Clin Neurosci. 2011 Mar;18(3):347-51. doi: 10.1016/j.jocn.2010.05.036. Epub 2011 Jan 14.

PMID:
21237660
15.

Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series.

Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D.

Neurosurgery. 1999 Jul;45(1):17-22; discussion 22-3.

PMID:
10414561
16.

[Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].

Yoshida M, Yamaguchi S, Ishi Y, Endo S, Motegi H, Kobayashi H, Asaoka K, Kamoshima Y, Terasaka S, Houkin K.

No Shinkei Geka. 2015 Jul;43(7):603-10. doi: 10.11477/mf.1436203084. Japanese.

PMID:
26136324
17.

Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas.

McGirt MJ, Chaichana KL, Gathinji M, Attenello F, Than K, Ruiz AJ, Olivi A, Quiñones-Hinojosa A.

Neurosurgery. 2008 Aug;63(2):286-91; discussion 291. doi: 10.1227/01.NEU.0000315282.61035.48.

PMID:
18797358
18.

High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.

Durando X, Lemaire JJ, Tortochaux J, Van-Praagh I, Kwiatkowski F, Vincent C, Bailly C, Verrelle P, Irthum B, Chazal J, Bay JO.

Bone Marrow Transplant. 2003 Apr;31(7):559-64.

PMID:
12692621
19.

Candida parapsilosis meningitis associated with Gliadel (BCNU) wafer implants.

O'Brien D, Cotter M, Lim CH, Sattar MT, Smyth E, Fitzpatrick F.

Br J Neurosurg. 2011 Apr;25(2):289-91. doi: 10.3109/02688697.2010.534202. Epub 2010 Dec 15.

PMID:
21158511
20.

Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma.

Sardi I, Sanzo M, Giordano F, Sandri A, Mussa F, Donati PA, Genitori L.

Oncol Rep. 2008 May;19(5):1219-23.

PMID:
18425379

Supplemental Content

Support Center